Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Clinical Genomics Technologies Closes $26M Financing Round

Clinical Genomics Technologies Closes $26M Financing Round

Jun 01, 2018
|
staff reporter

NEW YORK (GenomeWeb) – Clinical Genomics Technologies announced today that it has completed a $26 million financing round.

The company said it will use the proceeds from the financing to commercialize Colvera, its liquid biopsy test for earlier detection of recurrent colorectal cancer, and to advance Colvera for use in CRC screening.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Boosting Viral Surveillance

The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.

California Strain

The New York Times reports that Cedars-Sinai researchers have uncovered a new strain of SARS-CoV-2 in Southern California.

Nucleic Acids Research Studies on Pan-Cancer MiRNA Biogenesis Mutations, Skeletal Methylation, More

In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.

Lander Nominated for Science Advisor

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.

What's Popular?

In Business News

  1. Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M

  2. CMS Finalizes Blood-Based Colon Cancer Screening NCD with Non-Coverage for Epi ProColon

  3. Bionano Genomics to Raise $200M in Public Stock Offering

  4. Lucira Health Files for $115M IPO

  5. Bio-Rad, United Biomedical Get FDA Emergency Use Authorizations for Coronavirus Tests

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.